Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | POR | P16435 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | KCNA3 | P22001 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31120928 | 1.00 | CYP1A2 (0.39) | CYP1A2NQO1PORCYP2A6CYP3A4 | |
| SCHEMBL298025 | 0.81 | CYP1A2 (0.33) | CYP1A2HTR2A | |
| SCHEMBL10455673 | 0.81 | OPRK1 (0.38) | CYP1A2CYP3A4KDM4EKCNA3ALDH1A1 | |
| SCHEMBL16844564 | 0.81 | HTR2A (0.35) | NQO1PORALDH1A1HTR2AHTR2C | |
| SCHEMBL24819187 | 0.81 | CYP3A4 (0.33) | CYP3A4HPGDKDM4EKCNA3ALDH1A1 | |
| SCHEMBL24752718 | 0.81 | CYP3A4 (0.33) | CYP1A2CYP3A4HPGDKDM4EALDH1A1 | |
| SCHEMBL5153438 | 0.81 | HTR2A (0.35) | CYP1A2NQO1PORALDH1A1HTR2A | |
| SCHEMBL6948759 | 0.81 | RARA (0.33) | CYP1A2CYP3A4HPGDCCR1CCR5 | |
| SCHEMBL18876068 | 0.81 | RARA (0.33) | CYP1A2CYP2A6CYP3A4HPGDALDH1A1 | |
| SCHEMBL15280201 | 0.78 | HSD17B10 (0.36) | CYP1A2NQO1PORPOLBKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233842-B1 | BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARB) AGONISTS | KING S COLLEGE LONDON (GB) | 2025-03-26 | — | — | EP | disclosed |
| EP-4129989-A1 | NITRILE DERIVATIVE THAT ACTS AS INHIBITOR OF DIPEPTIDYL PEPTIDASE 1 AND USE THEREOF | Haisco Pharmaceuticals Pte. Ltd. (SG) | 2023-02-08 | — | — | EP | disclosed |
| US-11401265-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON | 2022-08-02 | — | — | US | disclosed |
| US-11370740-B2 | Method for producing ester group-containing compound | DIC CORPORATION (JP) | 2022-06-28 | — | — | US | disclosed |
| EP-3971260-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2022-03-23 | — | — | EP | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-11193065-B2 | Liquid crystal composition, method of producing the same, and retardation film constituted from the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-12-07 | — | — | US | disclosed |
| EP-3247701-B1 | ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-09-22 | — | — | EP | disclosed |
| CN-108219945-B | Flower water essential oil and multi-fragrance flower water essential oil | 河南科技大学 | 2021-07-30 | — | — | CN | disclosed |
| CN-108424813-B | Compound salt and compound salt solution for flower aromatic water and flower aromatic water extraction | 河南科技大学 | 2021-07-27 | — | — | CN | disclosed |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2004069840-A2 | PRODUCTION OF TETRAHYDROQUINOLINE BENZOFURANS | Grünenthal GmbH (DE) | 2004-08-19 | — | — | WO | disclosed |
| US-6358995-B1 | AGONIST FOR RETINOIC ACID RECEPTORS; CAN BE SUBSTITUTED FOR RETINOIC ACID AS PREVENTIVE AND THERAPEUTIC DRUGS FOR VARIOUS DISEASES OR CANCERS, SUCH AS ACUTE PROMYELOCYTIC LEUKEMIA. | EISAI CO., LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| US-6355669-B1 | THERAPY FOR KIDNEY DISEASE USING BENZOIC ACID COMPOUND | EISAI CO., LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-6258811-B1 | ADMINISTERING RETINOIC ACID RECEPTOR AGONIST | EISAI CO., LTD. (JP) | 2001-07-10 | — | — | US | disclosed |
| US-6121309-A | SUCH AS 4-(2-(5-(7-FLUORO-4-TRIFLUOROMETHYLBENZOFURAN-2-YL)PYRROLYL)) BENZOIC ACID; RETINOIC ACID RECEPTOR AGONISM | EISAI CO., LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| US-6110959-A | A RETINOIC ACID RECEPTOR AGONIST | EISAI CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-1025857-A1 | RETINOIC ACID AGONISTS AS PREVENTIVE AND THERAPEUTIC AGENTS FOR NEPHRITIS | Eisai Co., Ltd. (JP) | 2000-08-09 | — | — | EP | disclosed |
| EP-0930075-A1 | METHODS FOR PREVENTING, INHIBITING OR TREATING GRAFT REJECTION REACTIONS IN GRAFT-VERSUS-HOST DISEASE (GVHD) AND ORGAN TRANSPLANTATION | Eisai Co., Ltd. (JP) | 1999-07-21 | — | — | EP | disclosed |
| EP-0889032-A1 | FUSED-RING CARBOXYLIC ACID DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401265-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | RARB, RARA, RXRB | CYP1A2 1305/4885NQO1 625/4885POR 2704/4885 |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | ESR1, ESR2, GPER1 | CYP1A2 103/4885NQO1 840/4885POR 367/4885 |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | CYP1A2 572/4885NQO1 79/4885POR 1235/4885 |
| US-11370740-B2 | Method for producing ester group-containing compound | COASY, TAF5, TAF9 | CYP1A2 1185/4885NQO1 1396/4885POR 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.